破发股诚达药业跌7.66% 上市超募11亿光大证券保荐

中金财经

Aug 21

　　中国经济网北京8月21日讯诚达药业(301201.SZ)今日收报35.80元，跌幅7.66%。　　诚达药业于2022年1月20日在深交所创业板上市，公开发行新股2,417.4035万股，发行价格为72.69元/股，保荐机构(主承销商)为光大证券，保荐代表人为杨科、范国祖。　　上市首日，诚达药业盘中最高报188.00元，为该股上市以来最高点。该股目前处于破发状态。　　诚达药业首次公开发行股票募集资金总额为175,721.06万元，扣除发行费用后募集资金净额162,144.75万元。诚达药业实际募资净额比原拟募集资金多110,816.71万元。诚达药业于2022年1月14日披露的招股说明书显示，该公司原拟募集资金51,328.04万元，分别用于“医药中间体项目、原料药项目及研发中心扩建项目”和“补充流动资金”。　　诚达药业首次公开发行股票发行费用总额为13,576.31万元，其中，保荐承销费用11,792.90万元。　　诚达药业实际控制人为葛建利、卢刚、卢瑾，其中卢瑾为中国国籍，拥有加拿大永久居留权。　　诚达药业于2023年7月3日披露分红方案，每10股转增6股，派息(税前)3元。　　(责任编辑：魏京婷)

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Most Discussed

1
2
3
4
5
6
7
8
9
10

{"basename":"","ssrTDKData":{"titleTemplate":"%s - Tiger Brokers","title":"Tiger Brokers | Global Stocks, Options & Futures Trading App","description":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","keywords":"tiger brokers,tiger trade,tiger brokers singapore,broker online,stock trading in singapore,share trading singapore,brokerage firm singapore,trading app,stock broker singapore,stock trading platforms,trading account","social":{"ogDescription":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.0a0bd8dc.png","ogUrl":"https://www.itiger.com/news/2661426683"},"companyName":"Tiger Brokers"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental"},"isCrawlerRequest":true,"__swrFallback__":{"@#url:\"https://stock-news.skytigris.cn/v3/news\",params:#id:\"2661426683\",edition:\"fundamental\",auth_exemption:1,,,undefined,":{"share":"https://ttm.financial/m/news/2661426683?lang=en_US&edition=fundamental","thumbnail":"","is_english":false,"pubTime":"2026-08-21 16:54","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2661426683","market":"hk","top_or_hot":-1,"title":"破发股诚达药业跌7.66% 上市超募11亿光大证券保荐","media":"中金财经","content":"<html><body><p>　　中国经济网北京8月21日讯 <a href=\"https://laohu8.com/S/301201\">诚达药业</a>(301201.SZ)今日收报35.80元，跌幅7.66%。\r\n\r\n　　诚达药业于2022年1月20日在深交所创业板上市，公开发行新股2,417.4035万股，发行价格为72.69元/股，保荐机构(主承销商)为<a href=\"https://laohu8.com/S/601788\">光大证券</a>，保荐代表人为杨科、范国祖。\r\n\r\n　　上市首日，诚达药业盘中最高报188.00元，为该股上市以来最高点。该股目前处于破发状态。\r\n\r\n　　诚达药业首次公开发行股票募集资金总额为175,721.06万元，扣除发行费用后募集资金净额162,144.75万元。诚达药业实际募资净额比原拟募集资金多110,816.71万元。诚达药业于2022年1月14日披露的招股说明书显示，该公司原拟募集资金51,328.04万元，分别用于“医药中间体项目、原料药项目及研发中心扩建项目”和“补充流动资金”。\r\n\r\n　　诚达药业首次公开发行股票发行费用总额为13,576.31万元，其中，保荐承销费用11,792.90万元。\r\n\r\n　　诚达药业实际控制人为葛建利、卢刚、卢瑾，其中卢瑾为中国国籍，拥有加拿大永久居留权。\r\n\r\n　　诚达药业于2023年7月3日披露分红方案，每10股转增6股，派息(税前)3元。\r\n\r\n　　(责任编辑：魏京婷)        </p></body></html>","source":"zhongjincaijing_highlight","html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>破发股诚达药业跌7.66% 上市超募11亿光大证券保荐</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\n破发股诚达药业跌7.66% 上市超募11亿光大证券保荐\n</h2>\n\n<h4 class=\"meta\">\n\n\n2026-08-21 16:54 北京时间&nbsp;&nbsp;&nbsp;<a href=http://sc.stock.cnfol.com/gushijujiao/20260821/32342833.shtml><strong>中金财经</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>中国经济网北京8月21日讯 诚达药业(301201.SZ)今日收报35.80元，跌幅7.66%。\r\n\r\n　　诚达药业于2022年1月20日在深交所创业板上市，公开发行新股2,417.4035万股，发行价格为72.69元/股，保荐机构(主承销商)为光大证券，保荐代表人为杨科、范国祖。\r\n\r\n　　上市首日，诚达药业盘中最高报188.00元，为该股上市以来最高点。该股目前处于破发状态。\r\n\r\n　　诚达...</p>\n\n<a href=\"http://sc.stock.cnfol.com/gushijujiao/20260821/32342833.shtml\">Source Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"BK0183","symbol_name":"MSCI概念","start_time":0,"source_url":"http://sc.stock.cnfol.com/gushijujiao/20260821/32342833.shtml","article_id":"2661426683","we_media_id":null,"thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2661426683","pubTimestamp":1787302446,"columns":[],"sourceInfo":{"source_id":"zhongjincaijing_highlight","name":"中金在线"},"weMediaInfo":null,"summary":"中国经济网北京8月21日讯 诚达药业 今日收报35.80元，跌幅7.66%。　　诚达药业于2022年1月20日在深交所创业板上市，公开发行新股2,417.4035万股，发行价格为72.69元/股，保荐机构为光大证券，保荐代表人为杨科、范国祖。　　上市首日，诚达药业盘中最高报188.00元，为该股上市以来最高点。　　诚达药业首次公开发行股票发行费用总额为13,576.31万元，其中，保荐承销费用11,792.90万元。　　诚达药业于2023年7月3日披露分红方案，每10股转增6股，派息(税前)3元。","collect":0,"end_time":0,"defaultTopTitle":"cnfol.com","property":[],"viewcount":null,"language":"zh","relate_stocks":{"301201":"诚达药业","601788":"光大证券","BK0183":"MSCI概念","BK0012":"证金概念","BK0188":"融资融券","BK1147":"投资银行业与经纪业","IPOS":"Renaissance International IPO ETF","BK1564":"中资券商股","BK0239":"医药制造","06178":"光大证券","BK0028":"国家队","BK0276":"资本市场"},"translate_title":"Chengda Pharmaceutical, a broken stock, fell 7.66%, listed and over-raised 1.1 billion Everbright Securities sponsored","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"301201":1.5,"601788":1.5,"IPOS":1.5,"06178":1.5},"content_text":"中国经济网北京8月21日讯 诚达药业(301201.SZ)今日收报35.80元，跌幅7.66%。\n\n　　诚达药业于2022年1月20日在深交所创业板上市，公开发行新股2,417.4035万股，发行价格为72.69元/股，保荐机构(主承销商)为光大证券，保荐代表人为杨科、范国祖。\n\n　　上市首日，诚达药业盘中最高报188.00元，为该股上市以来最高点。该股目前处于破发状态。\n\n　　诚达药业首次公开发行股票募集资金总额为175,721.06万元，扣除发行费用后募集资金净额162,144.75万元。诚达药业实际募资净额比原拟募集资金多110,816.71万元。诚达药业于2022年1月14日披露的招股说明书显示，该公司原拟募集资金51,328.04万元，分别用于“医药中间体项目、原料药项目及研发中心扩建项目”和“补充流动资金”。\n\n　　诚达药业首次公开发行股票发行费用总额为13,576.31万元，其中，保荐承销费用11,792.90万元。\n\n　　诚达药业实际控制人为葛建利、卢刚、卢瑾，其中卢瑾为中国国籍，拥有加拿大永久居留权。\n\n　　诚达药业于2023年7月3日披露分红方案，每10股转增6股，派息(税前)3元。\n\n　　(责任编辑：魏京婷)","kind":"highlight","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":false,"editions":null,"column":"","sentiment":"-2","news_tag":"","news_rank":0,"isVideo":false,"video":null,"symbols":[],"gpt_button":1,"need_auth":false,"need_login_tip":false,"code":"91000000","status":"200"}}}